Dirican N.Bagci Ö.Uz E.Öztürk Ö.Bircan H.Dirican A.2024-07-222024-07-22201613090720http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16016We described heterozygous deletion of tumor protein 53 (TP53) gene in 11 patients including 2 patients with non-malignant diseases (pneumonia) and 9 patients with malignant diseases [including small cell lung cancer (n = 3), non-small cell lung carcinoma (n = 4), non-Hodgkin’s lymphoma (n=1), and gastric carcinoma (n=1)]. Chromosomal aberrant status was analyzed by fluorescence in situ hybridization with centromere specific and 17p13.1 locus specific probes. In 3 of 9 cancer patients we did not find malignant pleural effusion with histological examination and/or closed pleural biopsy. Heterozygous deletion of TP53 gene was found to be significantly higher in patients with malignant disease when compared to the patients with benign pleural fluid. As a result, we suggest that heterozygous deletion of TP53 may have indicator value for malignancy; however further studies are warranted to confirm this suggestion in large patient cohorts. © 2016, Journal of Clinical and Analytical Medicine. All Rights Reserved.EnglishAll Open Access; Bronze Open Accessadultadvanced canceragedArticlecancer stagingcase studycentromerechromosome 17pclinical articlecohort analysiscontrolled studyfemalefluorescence in situ hybridizationgene deletiongene locusgenetic associationheterozygotehumanhuman tissuemalemalignant pleura effusionmiddle agednon small cell lung cancernonhodgkin lymphomapleura biopsypleura fluidpneumoniasmall cell lung cancerstomach carcinomatumor suppressor genevery elderlyArticle10.4328/JCAM.4551